RSA Viewpoints
Finding talent for late stage neuroscience drug development
At a recent OBN/One Nucleus BioTuesday focusing on neurodegenerative diseases, I heard again the extent of the challenge faced by scientists wanting to develop...
Efficient engagement with executive search
When looking for a new role, you’ll have plenty of questions for a potential new employer. Ahead of any interview, you’ll do your due...
Lateral thinking for oncology leadership
The rapid growth in immuno-oncology therapeutics is causing talent headaches for the pharma industry Patients are already benefitting from pharma’s success in developing new...
New talent needed for a new era of market access in the medtech industry
The last decade has seen the unprecedented growth of innovative and improved medical technologies. In turn, this has led to the development of a...
RSA Talent Equity® | 2nd Annual Successful Biotech Boards
This is the second of our annual Talent Equity® reports analysing the performance of biotech Boards, CEOs and Chairs in Europe and the USA....
Pharmaceutical Market Europe | Adding value to company leadership
For a forward-looking industry, the life science sector is remarkably conservative, rarely looking outside for talent and often trying to home-grow its skills. In...
RSA Viewpoint | Life Sciences leadership in flux
Leadership and talent agendas in the life sciences are adapting to major external influences on the life sciences sector – economic, political, technological and...
The UK is a leader in life sciences. How can we make sure that it remains No.1 in Europe?
After spending a day in mid-October at this year’s excellent UK BioScience Forum, I was left with one particular thought ringing loud and clear...
How hiring the best leaders maximizes biotech exit values
We’ve seen some major exits in the biotech market in 2017. Early in the year, in Switzerland alone, Actelion was sold to Johnson &...
Recruitment International | The key to success in life sciences
Alex Bennett, CEO of The RSA Group, discusses the current opportunities and leadership challenges in the life sciences sector – and how to succeed...
RSA Viewpoint | The Successful Leader
There’s no doubt the leader’s job is becoming increasingly difficult in today’s environment. We’re experiencing unprecedented levels of change – societal, political, economic and...
Engaging with executive interims – time for a fresh perspective
Habits are hard to break and all too often we return to established patterns of behaviour rather than looking for innovative ways to do...
Diversity: A call to arms for Biotech Leaders and Investors
A panel discussion, led by The RSA Group, at the recent BIA UK CEO & Investor Forum discussed the demographic time bomb facing biotech boards...
The value of engaging Pharmacoeconomic executive interims
So what is Pharmacoeconomics? Pharmacoeconomics, is the “scientific discipline which evaluates the clinical, economic and humanistic aspects of pharmaceutical products, services, and programmes, as...
Pharmaceutical Market Europe | Massive Uncertainty is the new norm
There’s a lot of change coming: changes of practice, thinking and behaviour, all of which represent challenge and opportunity. Those leaders who recognise it...